An Open-label Phase II Trial of Erlotinib and Bevacizumab in Patients With Advanced Non-small Cell Lung Cancer and Activating EGFR Mutations.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 13 Nov 2017
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Biomarker; Pharmacogenomic; Therapeutic Use
- Acronyms BELIEF
- 07 Nov 2017 Planned End Date changed from 1 Oct 2017 to 1 Dec 2017.
- 07 Nov 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History